Alzamend Neuro Files 8-K on Equity Sales
Ticker: ALZN · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities, filing
TL;DR
Alzamend Neuro sold unregistered equity, filing an 8-K on 10/9/25.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on October 9, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Atlanta, GA.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the sale of unregistered equity. Investors should monitor future filings for details on the terms and impact of these sales.
Risk Assessment
Risk Level: medium — The sale of unregistered equity can lead to dilution and may signal a need for capital, potentially impacting stock value.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- October 9, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Atlanta, GA (location) — Principal Executive Offices
FAQ
What specific type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type in the provided text.
Were these sales to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities,' which often implies sales to accredited investors, but this is not explicitly stated in the provided text.
What is the total number of shares sold and the price per share?
The provided text of the 8-K filing does not contain details on the number of shares sold or the price per share.
What is the purpose of these unregistered equity sales?
The purpose of the unregistered equity sales is not detailed in the provided excerpt of the 8-K filing.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K filing was on October 9, 2025.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-09 16:30:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
Filing Documents
- o1082528k.htm (8-K) — 24KB
- 0001214659-25-014818.txt ( ) — 188KB
- alzn-20251009.xsd (EX-101.SCH) — 3KB
- alzn-20251009_lab.xml (EX-101.LAB) — 33KB
- alzn-20251009_pre.xml (EX-101.PRE) — 22KB
- o1082528k_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. Between October 1, 2025 and October 8, 2025, Alzamend Neuro, Inc. (the " Company ") issued an aggregate of 361,743 shares of common stock, par value $0.0001 per share (" Common Stock ") upon conversion of an aggregate of approximately 839.2 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act. As of October 8, 2025, the Company had 3,801,604 shares of Common Stock outstanding.
01 Financial Statements And Exhibits
Item 9.01 Financial Statements And Exhibits (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: October 9, 2025 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel 3